PBXIP1

Across TCGA pan-cancer cohorts, PBXIP1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PBXIP1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PBXIP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PBXIP1 expression acts as an unfavorable survival marker.

OV, CESC, and COAD are the cancer types where PBXIP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.021	0.844	<.001	36	view →
CESC	DFS	Median	II,III,IV	0.144	0.705	.004	24	view →
COAD	OS	Median	III,IV	0.238	0.702	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PBXIP1–OV (OS)

Open the OV breakdown →